PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27566219-2	2016	Adjuvant recombinant human erythropoietin (rHuEPO) has been used in patients who refuse blood transfusions, have a low response to treatment with iron sulfate, have limited time before birth, or have other illnesses that complicate the anemia.	ferrous sulfate	146-158	erythropoietin	Homo sapiens	27-41	
7531047-11	1994	A high dose of oral ferrous sulfate (300 mg) was given 11 days in advance of rHu EPO.	ferrous sulfate	20-35	erythropoietin	Homo sapiens	81-84	
10850644-6	2000	The absorption of 50 mg of iron as ferrous sulfate increased 2.4-fold from 3.8% to 9.4% (P < .05) when given without food and 4.2-fold from 1.4% to 5.9% (P < .05) when given with food after erythropoietin administration.	ferrous sulfate	35-50	erythropoietin	Homo sapiens	196-210	
10778761-3	2000	The results of a series of clinical studies published in the last decade allow some general observations: 1. the administration of erythropoietin, especially if associated to ferrous sulfate is able to increase hemoglobulin levels in cancer patients undergoing radiation therapy (combined with concomitant chemotherapy); 2.	ferrous sulfate	175-190	erythropoietin	Homo sapiens	131-145	
9328369-8	1997	In a long-term study over 5 months in patients on a stable maintenance dose of EPO, a gradual decline in total body iron occurred, even in subjects with initial adequate iron stores, and despite taking 50 mg elemental iron daily as oral ferrous sulphate.	ferrous sulfate	237-253	erythropoietin	Homo sapiens	79-82